Deadline fast approaching for Canadians to file claim in class-action drug suit
Canadians have until August 27 to file claims in a $4.75 million class-action settlement regarding the drug Rexulti.Summary
Canadians have until August 27 to file claims for a share of a $4.75 million class-action settlement involving the antipsychotic medication Rexulti. The settlement, approved by the Quebec Superior Court, addresses claims against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. regarding the drug's use in treating schizophrenia and depression.
The class action covers individuals prescribed Rexulti since February 2017 who subsequently developed impulse-control disorders, such as compulsive gambling, shopping, or binge-eating. While the settlement represents a compromise and includes no admission of liability from the pharmaceutical companies, it provides compensation for affected patients.
Potential payouts vary significantly based on the severity of the condition, ranging from approximately $6,500 for mild cases to over $102,000 for more severe instances.
(Source：BayToday)